Dynamics of circulating tumor DNA represented by the activating and resistant mutations in the EGFR-TKI treatment

Junji Uchida(Duke Medical Center), Kikuya Kato(Nara Institute of Science and Technology)

Kyoto University Research Information Repository (Kyoto University)

March 1, 2016

Cited by 4

Related Papers

The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy

|The Journal of Experimental Medicine|2004|631

Monitoring gastric cancer progression with circulating tumour DNA

|British Journal of Cancer|2014|103

High-fidelity target sequencing of individual molecules identified using barcode sequences:<i>de novo</i>detection and absolute quantitation of mutations in plasma cell-free DNA from cancer patients

|DNA Research|2015|88

Analytical Performance of a Highly Sensitive System to Detect Gene Variants Using Next-Generation Sequencing for Lung Cancer Companion Diagnostics

|Diagnostics|2023|26

Early responses of <i>EGFR</i> circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment

|Oncotarget|2016|22